• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

FDA: Donor Screening of Zika Virus Unnecessary in United States

June 5, 2024

In 2015 and 2016, large outbreaks of the mosquito-borne Zika virus occurred in the Americas.  Infection with the Zika virus is usually asymptomatic or very mild. However, infection during pregnancy can cause microcephaly and has also been linked to Guillain-Barré syndrome. In 2016, local transmission of the virus in Texas and Florida prompted the U.S. Food and Drug Administration (FDA) to recommend screening blood donors for the Zika virus.  Cases peaked in 2016, and no confirmed cases of local transmission have occurred in the continental U.S. or its territories since 2017.  While the FDA will continue to monitor the epidemiology of the Zika virus, it does not currently consider the Zika virus a “relevant communicable disease agent or disease.”  Thus, the FDA has withdrawn the May 2018 guidance titled, “Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular Tissue-Based Products,” and donor screening for Zika virus is not currently needed. A change in the epidemiology of the Zika virus may prompt the FDA to reinstate measures to reduce transmission.

Reference:

Information for Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) Establishments Regarding FDA’s Determination that Zika Virus is no Longer a Relevant Communicable Disease Agent or Disease| FDA May 20, 2024.

 

 

Filed Under

  • Blood Donation
  • News
  • Quality Control and Regulatory

Recommended

  • Reducing the risk of transfusion transmitted Babesia: an AABB Report

  • Tracking HIV Drug Resistance and Subtypes in Blood Donors

  • RBC and Plasma Transfusions Decreased in the U.S. (2015-2018)

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley